Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT01500200

Public ClinicalTrials.gov record NCT01500200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Therapy

Study identification

NCT ID
NCT01500200
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
142 participants

Conditions and interventions

Interventions

  • ALKS 5461 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2011
Primary completion
Feb 28, 2013
Completion
Feb 28, 2013
Last update posted
May 20, 2019

2011 – 2013

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
27
Facility City State ZIP Site status
Alkermes Investigational Site Tucson Arizona 85712
Alkermes Investigational Site Oceanside California 92056
Alkermes Investigational Site Santa Ana California 92701
Alkermes Investigational Site Torrance California 90502
Alkermes Investigational Site Fort Myers Florida 33912
Alkermes Investigational Site Lauderhill Florida 33319
Alkermes Investigational Site Leesburg Florida 34748
Alkermes Investigational Site North Miami Florida 33161
Alkermes Investigational Site St. Petersburg Florida 33716
Alkermes Investigational Site Atlanta Georgia 30308
Alkermes Investigational Site Hoffman Estates Illinois 60169
Alkermes Investigational Site Baltimore Maryland 21285
Alkermes Investigational Site Boston Massachusetts 02135
Alkermes Investigational Site Haverhill Massachusetts 01830
Alkermes Investigational Site Berlin New Jersey 08009
Alkermes Investigational Site Brooklyn New York 11241
Alkermes Investigational Site New York New York 10021
Alkermes Investigational Site Canton Ohio 44718
Alkermes Investigational Site Dayton Ohio 45417
Alkermes Investigational Site Oklahoma City Oklahoma 73112
Alkermes Investigational Site Philadelphia Pennsylvania 19104
Alkermes Investigational Site Charleston South Carolina 29407
Alkermes Investigational Site Austin Texas 78754
Alkermes Investigational Site Dallas Texas 75235
Alkermes Investigational Site Houston Texas 77081
Alkermes Investigational Site San Antonio Texas 78229
Alkermes Investigational Site Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01500200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 20, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01500200 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →